Inhibrx
La Jolla, US · Founded 2017 · California corporation · 4 known investors
Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer. The company operates in the biotherapeutics and drug development industry.
Founders & leadership
Inhibrx was founded in 2017 by Mark Lappe and Brendan Eckelman.
ML
Mark LappeCo-founder
BE
Brendan EckelmanCo-founder
DF
Doug ForsythNamed on SEC filing
JF
Jon Faiz KayyemNamed on SEC filing
MF
Margery FischbeinNamed on SEC filing
Board
JL
Investors · 4
Reported raises · per SEC filings
Form D private placements$668.6M disclosed across 5 rounds · 2018–2023
▶$200MraisedAug 2023 · 5 investors · BiotechnologyRule 506(b)
▶$200MraisedAug 2023 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark LappeExecutive Officer, Director
- Kristiina VuoriDirector
- Kelly DeckExecutive Officer
- Jon KayyemDirector
- Brendan EckelmanExecutive Officer
- Kimberly ManhardDirector
- Douglas ForsythDirector
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Aug 2023
- Incorporated
- Corporation, California
- Federal exemptions
- 06b
▶$15MraisedApr 2020 · 5 investors · BiotechnologyRule 506(b)
▶$15MraisedApr 2020 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Judith LiDirector
- Jon KayyemDirector
- Kelly DeckExecutive Officer
- Doug ForsythDirector
- Brendan EckelmanExecutive Officer, Director
- Mark LappeExecutive Officer, Director
- Offering amount
- $30M
- Amount sold
- $15M
- First sale
- Apr 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$40MraisedMay 2019 · 1 investors · BiotechnologyRule 506(b)
▶$40MraisedMay 2019 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Kelly DeckExecutive Officer
- Judith LiDirector
- Doug ForsythDirector
- Margery FischbeinDirector
- Jon Faiz KayyemDirector
- Brendan EckelmanDirector
- Mark LappeExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.5MraisedMay 2018 · 6 investors · BiotechnologyRule 506(b)
▶$3.5MraisedMay 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jon Faiz KayyemDirector
- Brendan EckelmanDirector
- Margery FischbeinDirector
- Judith LiDirector
- Doug ForsythDirector
- Mark LappeExecutive Officer, Director
- Offering amount
- $75M
- Amount sold
- $3.5M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$410MraisedMay 2018 · 71 investors · BiotechnologyRule 506(b)
▶$410MraisedMay 2018 · 71 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mark LappeExecutive Officer, Director
- Doug ForsythDirector
- Brendan EckelmanDirector
- Judith LiDirector
- Jon Faiz KayyemDirector
- Margery FischbeinDirector
- Offering amount
- $410M
- Amount sold
- $410M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Seeking Alpha26 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Mission BioCapital Platinum Program Holdings LLC25 shared keywordsMission BioCapital is an early-stage venture capital firm that provides capital and shared lab space to life science startups, supporting founders from initial experiments through to the clinic. Founded in 2009, it invests in early-stage life science companies and is currently deploying its fifth fund.
Companies competing with Inhibrx for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $223.9K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Inhibrx do?
- Inhibrx develops protein therapeutics, using target biology and protein engineering to create therapeutic candidates in clinical trials for conditions including sarcoma and head and neck cancer. The company operates in the biotherapeutics and drug development industry.
- Who founded Inhibrx?
- Inhibrx was founded by Mark Lappe, Brendan Eckelman in 2017.
- Who are Inhibrx's investors?
- Inhibrx's investors include LAV, Lilly Asia Ventures, RA Capital, Oxford Finance LLC.
- How much funding has Inhibrx raised?
- Inhibrx has disclosed $668.6M raised across 5 rounds.
- Where is Inhibrx headquartered?
- Inhibrx is headquartered in La Jolla, US.